Evommune (NYSE:EVMN) Insider Sells $452,600.00 in Stock

Evommune, Inc. (NYSE:EVMN) insider Janice Suzann Drew sold 20,000 shares of Evommune stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $22.63, for a total value of $452,600.00. Following the sale, the insider owned 67,794 shares in the company, valued at $1,534,178.22. This trade represents a 22.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Evommune Stock Down 3.0%

Shares of NYSE EVMN traded down $0.72 during trading hours on Wednesday, reaching $23.53. The stock had a trading volume of 1,043,288 shares, compared to its average volume of 453,427. The firm has a 50-day moving average of $23.14 and a 200-day moving average of $22.27. Evommune, Inc. has a fifty-two week low of $13.89 and a fifty-two week high of $33.20.

Evommune (NYSE:EVMN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. Equities research analysts forecast that Evommune, Inc. will post -2.85 earnings per share for the current year.

Analysts Set New Price Targets

EVMN has been the subject of several research reports. Stifel Nicolaus started coverage on shares of Evommune in a research report on Friday, May 1st. They issued a “buy” rating and a $54.00 price target for the company. Clear Str raised shares of Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Oppenheimer assumed coverage on shares of Evommune in a report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 target price for the company. Wall Street Zen downgraded shares of Evommune from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $48.00 price target on shares of Evommune in a report on Friday, April 10th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Evommune presently has an average rating of “Buy” and a consensus price target of $49.25.

Institutional Investors Weigh In On Evommune

A number of hedge funds have recently added to or reduced their stakes in EVMN. Capricorn Fund Managers Ltd acquired a new position in Evommune during the 4th quarter worth approximately $1,027,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Evommune in the fourth quarter valued at approximately $34,000. Sectoral Asset Management Inc. purchased a new stake in shares of Evommune in the fourth quarter valued at approximately $10,084,000. Geode Capital Management LLC acquired a new position in Evommune during the fourth quarter worth $1,881,000. Finally, Seven Grand Managers LLC acquired a new position in Evommune during the fourth quarter worth $1,284,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.